Intellectual Frontiers

Turn unusual ideas into assets worth protecting.

Intellectual Frontiers IP identifies technical insight, operating know-how, inventions, data rights, methods, and other intellectual assets that may create unusual advantage. We test whether the advantage is real, decide what deserves protection, and preserve the rights needed to publish it, license it, invest behind it, or build around it.

A patent is evidence that something may be novel. It is not evidence that anybody wants it.

IP is a means, not the outcome.

Most IP strategies start with an invention and ask, can we patent this?

We start one step earlier. What unusual advantage have we found? Why does it matter? Who would care? What makes it hard to copy? Only then: what should we own, control, publish, license, or protect?

Sometimes the answer is a patent. Sometimes it is know-how, a trade secret, data rights, a contract, a trademark, a defensive disclosure, a publication, or just moving faster than everyone else.

Sometimes the right answer is to protect nothing.

Before we protect anything, we ask why it matters.

  1. 1

    What unusual insight or advantage have we actually found?

  2. 2

    Who cares enough about it to spend money, time, reputation, access, or another scarce resource?

  3. 3

    Is the advantage genuinely difficult to reproduce?

  4. 4

    What form of ownership or control would strengthen the advantage?

  5. 5

    Would protection create more value than publication, secrecy, speed, or simply doing nothing?

When a patent is a moat, and when it is not.

People call a patent a moat. Sometimes it is. Most of the time it is not.

A patent works as a moat when two things are true at once: a workaround is impractical or expensive, and you can tell when someone is infringing. Small molecules and specific device mechanisms often meet that bar.

When either condition fails, calling the patent a moat is wishful thinking. If a competitor can design around the claims in a weekend, if the infringement happens out of sight inside someone else's data center, or if suing costs more than the business earns, you do not have a moat. You have a filing receipt and a published recipe.

A patent can widen a moat that already exists. It cannot dig one where there is no operating advantage underneath.

Protect the advantage, not the artifact.

We call an unusual and disproportionate advantage Native Alpha. A patent can add to Native Alpha, but the patent itself is rarely the advantage.

The advantage is more often problem framing, accumulated know-how, customer access, workflow position, proprietary data, implementation experience, trust, regulatory position, distribution, or several of those together.

Our job is to work out what actually creates the advantage before deciding what deserves legal protection.

What can come out of IP work

Patents

When exclusion rights strengthen a commercially meaningful advantage.

Trade secrets and know-how

When disclosure would make the advantage easier to reproduce.

Defensive disclosures

When keeping an idea open is more valuable than owning it.

Research and publications

When explaining an idea strengthens the market, the thesis, or our understanding.

Data and contractual rights

When control over access, use, or relationships matters more than patent claims.

Trademarks

When names, methods, frameworks, or products need durable identity.

Licensing

When another organization is better positioned to commercialize the asset.

New ventures

When the IP contributes to an advantage strong enough to justify building a company around it.

Investments

When the insight shows someone else is already building the right company and Intellectual Frontiers Capital should consider backing them instead.

IP work can end up in Press, Capital, Studios, or an outside commercial relationship. Studios does not automatically build everything that starts here.

Things we do not confuse with evidence

  • A patent is not proof of customer demand.
  • A patent is not proof of freedom to operate.
  • A patent is not proof that infringement can be detected.
  • A patent is not proof that enforcement is economical.
  • A large market is not proof that this particular invention matters.
  • Technical novelty is not proof of commercial value.
  • An impressive inventor résumé is not proof that an invention deserves another dollar.

IP earns its place when it changes a commercial decision.

Where we are looking for unusual advantage

All research

Research areas

  • Zero Security Theatre

    A control does not count just because it is there.

  • Engineering Care Delivery

    Engineering Care Delivery studies how care itself should be designed when technical capability becomes easier to produce but adoption, patient access, workflow, trust, reimbursement, accountability, and outcomes remain scarce.

  • Alpha to Patent

    Alpha to Patent starts with the advantage a customer values, traces it to the technical or operating constraint that creates the value, tests whether the advantage survives better AI and easier engineering, and then chooses the narrowest useful mix of patents, trade secrets, know-how, data rights, contracts, regulatory position, licensing, publication, and operating control.

  • Precision Education

    Precision Education treats the person, their context, and the evidence as the unit of learning rather than the course.

  • Unbundling Work

    Unbundling Work studies tasks, decisions, handoffs, authority, evidence, risk, and outcomes instead of treating the job title as the unit of analysis.

All areas

Patent portfolio

Full patent register

These are rights we hold or are pursuing. Their presence here means we thought the underlying work was worth keeping an option on. It does not mean every patent is commercially valuable, or that every family will become a product, a licence, or a company.

Portfolio areas

  • Healthcare delivery

    Referrals, care coordination, task and work list scheduling, patient navigation, and risk management. 7 families.

  • Medical devices

    Software inside and around regulated devices, and the data that moves off the device and into a chart. 3 families.

  • Clinical trials and research

    Running a study as software instead of a binder, with evidence produced while the trial runs. 1 family.

  • Insurance and digital authorization

    Self-controlled authorization to records and service delivery evidence. 3 families.

  • Payments, marketplaces, and credentialing

    Payment systems, settling marketplaces, crowdsourced credentialing, and reputation signals. 10 families.

  • Education, training, and system telemetry

    Precision education and training, rewardable content, and traceable operational telemetry. 6 families.

Not everything should become a patent.

Published papers

Peer-reviewed work with authors, journals, dates, and DOI links.

Trademarks

The names used for the firm's methods, services, and products.

Found something unusual?

Send us an invention, a technical observation, an operating problem, an unexpected result, or a pattern you keep seeing. We care more about the advantage underneath than about whether you already think it is patentable.

Submit a disclosure

IP is where we preserve options. It is not where every idea ends.

  • Intellectual Frontiers Press may turn the insight into something people can understand and use.
  • Intellectual Frontiers Capital may invest behind an outside company exploiting the same insight.
  • Intellectual Frontiers Studios may build a venture when the evidence is compelling and nobody else is pursuing it properly.
  • Intellectual Frontiers Network may find the people, operators, founders, specialists, customers, or partners who make the insight commercially useful.

The units are not a pipeline. Each encounter with reality changes the thesis. A Studios experiment can weaken an IP thesis. A publication can reveal stronger demand than we expected. An outside company can prove we should invest rather than build. A licensing conversation can show that a patent nobody cared about suddenly matters.

Interested in licensing, acquiring, implementing, challenging, or building around something here? Write to hello+ip@intellectualfrontiers.com and tell us what product, market, evidence, or decision you are working on. A useful conversation starts with the commercial problem, not the patent number.

Latest in research and IP

Everything that changed

  • NewResearch & IP

    Adversarial simulation may replace part of annual training

    Generated, varied, current scenarios delivered continuously and measured behaviourally are a plausible substitute for a yearly module. Plausible is not proven.

    Read more

  • NewResearch & IP

    Backups are usually out of scope, and usually full of the data

    Retention and deletion policies often exclude backups for practical reasons. The exclusion is defensible. Leaving it unstated in the notice is not.

    Read more

  • NewResearch & IP

    Consent language without enforcement is a claim about intent

    If withholding consent does not change what a system does with a record, the consent mechanism only keeps a record of the choice. It does not enforce it.

    Read more